Oncotype returns high false negative of Her2 results

[Hopeful]

http://abstract.asco.org/AbstView_102_82476.html

Hopeful

[gdpawel]

http://cancerfocus.org/forum/showthread.php?t=734

[Jackie07]

http://www.ncbi.nlm.nih.gov/pubmed?term=oncotype%20hype

Health Policy. (http://www.ncbi.nlm.nih.gov/pubmed?term=oncotype%20hype#) 2010 Feb;94(2):91-100. Epub 2009 Oct 7.
Personalized medicine: factors influencing reimbursement.

Meckley LM (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Meckley%20LM%22%5BAuthor%5D), Neumann PJ (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Neumann%20PJ%22%5BAuthor%5D).
Source

Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St., #63, Boston, MA 02111, USA. lmeckley@tuftsmedicalcenter.org

Abstract

OBJECTIVES:

Personalized medicine (PM) has attracted tremendous interest, but yielded few marketed products. We examined factors influencing the reimbursement of existing PM technologies.
METHODS:

We conducted six case studies of the following paired genetic tests and treatments: HER2/neu with trastuzumab (Herceptin); hepatitis C genotyping with ribavirin/pegylated interferon; Oncotype DX with chemotherapy; UGT1A1 with irinotecan (Camptosar); VKORC1/CYP2C9 with warfarin; BRCA1/2 with prophylactic surgical measures; and Oncotype DX with chemotherapy. We developed a framework for categorizing PM technology, and assessed factors influencing reimbursement, including quality of evidence, type of regulatory oversight, presence of clinical guidelines, and cost-effectiveness.
RESULTS:

PM is not a monolithic concept, but rather encompasses different types of technology. The strength of evidence available for existing PM technology varies widely and, along with endorsement of clinical guidelines, appears to be the strongest predictor of reimbursement. In the absence of reimbursement, direct-to-consumer marketing has continued for some PM technology. The type of regulatory oversight and the results of cost-effectiveness analysis do not appear to be associated with reimbursement to date.
CONCLUSIONS:

To date, the promise and hype of PM has outpaced its evidentiary support. In order to achieve favorable coverage and reimbursement and to support premium prices for PM, manufacturers will need to bring better clinical evidence to the marketplace and better establish the value of their products.